phase 3
Dyax Corp. (DYAX) Reports Statistically Significant Results in Trials to Fight Hereditary Angioedema
Read the full article: http://blog.qualitystocks.net/?p=11807
Dyax Corp. (Nasdaq: DYAX) is a clinical-stage drug company focused on the discovery, development and commercialization of biotherapeutics for oncology and inflammatory conditions.
- Login or register to post comments
- Read more
- Email this page
AtheroGenics Inc. (AGIX) Reports Positive Clinical Trial Results for Type 2 Diabetes Treatment
Read the full article: http://blog.qualitystocks.net/?p=11508
AtheroGenics Inc. (Nasdaq: AGIX) is a pharmaceutical company focused on the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. The company today announced top-line results from its ANDES phase 3 clinical trial of AGI-1067, the company’s lead antioxidant and anti-inflammatory drug candidate for the treatment of type 2 diabetes.
- Login or register to post comments
- Email this page
Related Articles
- Dyax Corp. (DYAX) Reports Statistically Significant Results in Trials to Fight Hereditary Angioedema
- Dyax Corp. (DYAX) Announces Completion of Biologics License Application with FDA; Moves Forward with Treatment for Life-Threaten
- AtheroGenics Inc. (AGIX) Reports Positive Clinical Trial Results for Type 2 Diabetes Treatment
- GenVec, Inc.’s (GNVC) TNFerade™ Gets FDA Fast Track Designation for Pancreatic Cancer Treatment
- CardioVascular Biotherapeutics Inc. (CVBT.OB) Finds Significant Private Funding for Topical Diabetic Wound Care Rollout